Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.38 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.37 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764240 | 0.95 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2IKZF1 | |
| SCHEMBL24764816 | 0.95 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2IKZF1 | |
| SCHEMBL24765107 | 0.92 | CRBN (0.61) | CRBNDDB1IKZF3IKZF2 | |
| SCHEMBL24765085 | 0.88 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2IKZF1 | |
| SCHEMBL21996869 | 0.87 | CRBN (0.60) | CRBNDDB1IKZF3IKZF2IKZF1 | |
| SCHEMBL24379869 | 0.87 | CRBN (0.60) | CRBNDDB1IKZF3IKZF2 | |
| SCHEMBL24764991 | 0.87 | CRBN (0.58) | CRBNDDB1IKZF3IKZF2IKZF1 | |
| SCHEMBL24764988 | 0.86 | CRBN (0.57) | CRBNDDB1IKZF3IKZF2IKZF1 | |
| SCHEMBL21996711 | 0.85 | CRBN (0.62) | CRBNDDB1IKZF3IKZF2IKZF1 | |
| SCHEMBL25585838 | 0.85 | CRBN (0.64) | CRBNDDB1IKZF3IKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | CRBN 183/4885DDB1 3837/4885IKZF3 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.